Afsaneh Barzi, MD, PhD

Clinical pearls regarding molecular testing and treatment selection in metastatic cholangiocarcinoma.

Implications for treating select patients with metastatic cholangiocarcinoma with ivosidenib as second-line therapy.

Insight pertaining to the use of infigratinib and pemigatinib, FGFR inhibitors, as second-line therapy for metastatic cholangiocarcinoma.

An overview of the standard of care for patients with metastatic cholangiocarcinoma, and the significance of conducting clinical trials that increase the number and types of therapies available to patients with fewer adverse events and better results.

Recommendations for conducting molecular testing and biopsies to learn more about patients who present with metastatic cholangiocarcinoma.

Dr Afsaneh Barzi explains why screening measures for cholangiocarcinoma are so important to patient outcomes.

Reactions to the management of metastatic cholangiocarcinoma and prediction of patient response to treatments used in early lines of therapy.

Afsaneh Barzi, MD, PhD, shares impressions of the overall care for an elderly man with metastatic cholangiocarcinoma and recommends how to care for patients who experience treatment-related adverse events from initial therapy.